Fig. 1: CD84 expression on leukemic blasts and healthy bone marrow cells. | Leukemia

Fig. 1: CD84 expression on leukemic blasts and healthy bone marrow cells.

From: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Fig. 1

A Percentage of CD84, CD123, and CD33-positive cells in primary AML patient samples, with the median indicated (n = 51 AML patient samples). B The normalized mean fluorescence intensity (nMFI) of CD84, CD123, and CD33 in primary AML patient samples, calculated as the ratio of the MFI of cells stained with specific antibodies to the MFI of cells stained with isotype controls (median is shown; n = 51 AML patient samples). See Supplementary Table 1 for AML diagnoses. C The nMFI of CD84 expression was analyzed as the ratio of the MFI of cells stained with the specific anti-CD84 antibody to the MFI of cells stained with the isotype control. Eight samples were analyzed (n = 8: 5 healthy donor bone marrow samples and 3 samples from individuals with monoclonal gammopathy of undetermined significance) (median is represented).

Back to article page